Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunovative, Inc. Announces the Appointment of Members to the Scientific Advisory Board

Published: Tuesday, September 04, 2012
Last Updated: Tuesday, September 04, 2012
Bookmark and Share
The SAB serves as a Committee to the ITL Board of Directors and serves the joint interests of IMUN and ITL. Dr. Laurence Rulleau, PhD, a member of the IMUN Business Advisory Board, will represent IMUN at ITL SAB meetings.

Joining Dr. Rulleau and Dr. Katsanis, are five world-renowned medical scientists who bring expertise in key areas that will be invaluable in transitioning ITL from the current clinical development phase to commercialization.

The members of the Scientific Advisory Board are:

•    Lawrence Fong, MD, Associate Professor of Medicine, Division of Hematology/Oncology at the University of California, San Francisco. Dr. Fong is a specialist in urologic oncology and an expert in tumor immunology and developing cancer vaccines.

•    Diego Martin, MD, PhD, Professor of Radiology and Head of the Department of Medical Imaging at the University of Arizona. Dr. Martin is an internationally recognized leader in MRI technology for the diagnosis and monitoring of disease.

•    Frank Ondrey, MD, PhD, Associate Professor of Medicine and Director of the Molecular Oncology Program at the University of Minnesota. Dr. Ondrey is a head and neck cancer surgeon board certified in otolaryngology.

•    Antoni Ribas, MD, PhD, Professor of Medicine, Hematology/Oncology, Surgical Oncology and Director of the Cell and Gene Therapy Core Facility at the University of California, Los Angeles. Dr. Ribas is a specialist in tumor immunology and cancer vaccine development and clinical trials in immunotherapy.

•    Theresa Whiteside, PhD, Professor of Pathology, Immunology and Otolaryngology at University of Pittsburgh School of Medicine. Dr. Whiteside serves as Laboratory Director of Immunologic Monitoring and Cellular Products Laboratory at University of Pittsburgh Cancer Institute.

"We are very pleased to bring together these key thought leaders to establish the Immunovative Therapies, Ltd. Scientific Advisory Board," stated Dr. Emmanuel Katsanis, Immunovative's Chief Medical Officer. "Their deep insight into immunological mechanisms of cancer, the design, analysis, imaging, pathological and immunological monitoring of clinical trials will be instrumental in advancing and expanding our therapeutic programs."

Dr. Michael Har-Noy, Founder and CEO of Immunovative Therapies, stated: "We are honored and humbled that our technology is able to attract the interest and direct participation of these world class scientists and physicians on our SAB. We anticipate an active SAB and look forward to working closely with these experts in developing the strategies that will enable us to advance our immunotherapies and understand how they are working and how to improve them in order to provide patients with advanced cancer with alternatives to toxic treatment regimens. "

"During the past year, ITL has made important advances in the development of cell-based immunotherapy products," said Seth Shaw, CEO and Chairman of IMUN. "Preparations are now almost completed for launch of a randomized, controlled, Phase II/III clinical of the lead AlloStim™ product in advanced stages of metastatic breast cancer and for launch of a randomized Phase I/II clinical trial of AlloVax™ in advanced stages of Head and Neck cancer. The appointment of the SAB will be invaluable in overseeing the scientific analysis of data from these trials and in developing new products and improvements. The SAB will also assist in supporting our strategy to collaborate with academic medical centers to develop additional indications of AlloStim™ and AlloVax™ and in seeking and evaluating potential licensing partners."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Iron Regulators Join War on Pathogens
Iron regulatory proteins (IRPs) play an important role in the body’s immune system.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!